Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.

LabCorp (LH) Names Two Leaders for Major Business Wings

LabCorp (LH) will get to use Sysmex' advanced XN-9100 system, which is a scalable, modular automation system.

LabCorp to Expand Hematology Suite With Sysmex America Deal

LabCorp (LH) expands service portfolio through Covance's data management portal.

LabCorp's Covance Launches Laboratory Data Management Service

LabCorp (LH) reported earnings 30 days ago. What's next for the stock?

LabCorp (LH) Down 3.4% Since Last Earnings Report: Can It Rebound?

Let's see if Laboratory Corporation (LH) stock is a good choice for value-oriented investors right now from multiple angles.

Can Value Investors Pick Laboratory Corporation (LH) Stock?

The laboratory services giant posted mixed results in the second quarter and narrowed its full-year 2019 outlook.

What You'll Want to Know About LabCorp's Q2 Earnings Results

Laboratory Corporation of America Holdings (LH) CEO David King on Q2 2019 Results - Earnings Call Transcript

While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.

LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall

LabCorp (LH) delivered earnings and revenue surprises of 1.03% and -0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Tops Q2 Earnings Estimates

Baxter

ResMed

Stryker

West Pharmaceutical Services

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.

Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?

CFO, EVP of Laboratory Corp Of America Holdings (NYSE:LH) Glenn A Eisenberg sold 5,563 shares of LH on 07/08/2019 at an average price of $176.75 a share.

Laboratory Corp Of America Holdings (LH) CFO, EVP Glenn A Eisenberg Sold $983,260 of Shares

LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.

LabCorp Diagnostics Shows Robust Growth Amid Price Declines

Carlisle Companies

FleetCor Technologies

Starbucks

T. Rowe Price Group

Sales growth provides investors an insight into product demand and pricing power.

Robust Sales Growth Makes These Five Stocks Worth Buying Now

The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

Why Is LabCorp (LH) Up 1.6% Since Last Earnings Report?

Laboratory Corporation of America Holdings (LH) CEO David King on Q1 2019 Results - Earnings Call Transcript

Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.

LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates

Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

Rite Aid's board clears the way for a 1-for-20 reverse stock split later this month. Booking Holdings, LabCorp, and Citi have gone on to move higher after going this route.

3 Stocks That Survived Reverse Splits

LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Labcorp Holdings Inc Stock (LH)